6533b7dafe1ef96bd126e327

RESEARCH PRODUCT

Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: Results from an international, multi-institutional, retrospective analysis

Antonella BrunelloRobin L. JonesMarianna SillettaNadia HindiMargherita NanniniPeter HohenbergerMariella Spalato CerusoMarco VitellaroJavier Martin-brotoAngelo Paolo Dei TosChiara ColomboGiuseppe BadalamentiDaniele SantiniGiuseppe ToniniSpyridon GennatasBruno VincenziAlessandro GronchiSalvatore ProvenzanoToni IbrahimElena PalassiniSilvia StacchiottiSilvia GasperoniAndrea Napolitano

subject

Adultfamilial adenomatosis polyposiCancer Researchmedicine.medical_specialtyVincaAdolescentVinca alkaloidsdesmoidmedicine.medical_treatmentPopulationVinorelbinechemotherapyGastroenterologymethotrexatevinca alkaloidsYoung Adultchemotherapy; desmoid; familial adenomatosis polyposis; methotrexate; vinca alkaloidsLow-dose chemotherapyInternal medicinemedicineHumansChemotherapyChildeducationDesmoidSurvival analysisRetrospective StudiesChemotherapyeducation.field_of_studybiologybusiness.industryFamilial adenomatosis polyposisbiology.organism_classificationmedicine.diseasefamilial adenomatosis polyposisMethotrexateAdenomatous Polyposis ColiOncologyFemaleSarcomabusinessProgressive diseasemedicine.drug

description

[Introduction] Desmoid tumour (DT) is a locally aggressive fibroblastic proliferative disease representing the most common extraintestinal manifestation of familial adenomatosis polyposis (FAP). As data on the activity of chemotherapy in these patients are limited, we examined the outcomes of patients treated with low-dose methotrexate (MTX)+vinca alkaloids (vinorelbine or vinblastine).

yearjournalcountryeditionlanguage
2019-10-02
10.1136/esmoopen-2019-000604http://hdl.handle.net/10447/404742